Long-term trial of an alpha adrenoceptor blocking drug (Indoramin) in asthma. A preliminary report.

Abstract

Eight patients suffering from both asthma and migraine underwent a clinical trial for 3 months of indoramin, an alpha adrenoceptor antagonist with antihistamine and antiserotonin activity. Patients were told indoramin was prescribed for migraine prophylaxis. In three asthmatic patients there was a marked increase in airflow meter (AFM) readings which were recorded daily, the remaining five showing no significant change or a decrease in AFM readings. Indoramin did not appear to potentiate the action of the beta sympathomimetic aerosols. It is suggested that a small population of asthmatic patients may derive therapeutic benefit from an alpha adrenoceptor antagonist. Seven of the eight patients experienced a 50% decrease in the frequency of their migraine headaches.

• Authors: J L Black, D M Temple, S D Anderson
• Journal: Scandinavian journal of respiratory diseases (Scand J Respir Dis) Vol. 59 Issue 6 Pg. 307-12 ( 1978) ISSN: 0036-5572 [Print] Denmark
• PMID: 373090 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Bronchodilator Agents
• Indoles
• Indoramin

Topics

• Adolescent
• Adult
• Asthma (complications, drug therapy)
• Bronchodilator Agents (therapeutic use)
• Circadian Rhythm
• Clinical Trials as Topic
• Drug Evaluation
• Drug Synergism
• Female
• Humans
• Indoles (therapeutic use)
• Indoramin (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Migraine Disorders (complications, prevention & control)
• Pulmonary Ventilation (drug effects)